Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA Earnings Recaps

FRE.DE Health Care 1 recap
Next earnings: August 5, 2026 (estimated) · full calendar
Q3 2025 Nov 7, 2025

Fresenius reported a robust third quarter, with a significant EBIT growth guidance upgrade from 3-7% to 4-8%, supported by a strong performance in its Kabi and Helios segments.

Key takeaways
  • Core EPS surged by 14%, highlighting strong bottom-line performance driven by margin expansion and top-line growth.
  • Kabi achieved an impressive 16.7% EBIT margin, bolstered by newly launched products and strong progress in IV generics and biosimilars.
  • The Helios division maintained solid EBIT margins, showcasing resilience amid macroeconomic challenges.
  • Fresenius launched three new products focused on high-energy and protein needs in Q3, enhancing its MedTech portfolio.
  • The company returned to its self-imposed cash flow target corridor, reflecting disciplined financial management.
Full recap

Go deeper on FRE.DE and the wider market.

All earnings recaps Browse the latest results across the market. Stock directory Browse companies by sector and market. Highest-yield stocks A curated screen of top dividend payers. Investing glossary Plain-English definitions for every metric.